We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into TransMedics (TMDX) Q1: Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from TransMedics (TMDX - Free Report) is expected to reveal quarterly earnings of $0.29 per share, indicating a decline of 17.1% compared to the year-ago period. Analysts forecast revenues of $123.56 million, representing an increase of 27.6% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some TransMedics metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Net revenue by OCS product- OCS Lung net revenue' to reach $5.19 million. The estimate suggests a change of -8.4% year over year.
The consensus estimate for 'Net revenue by OCS product- OCS Liver net revenue' stands at $87.87 million. The estimate points to a change of +31.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net revenue by OCS product- OCS Heart net revenue' of $30.01 million. The estimate suggests a change of +28.6% year over year.
Analysts expect 'Geographic Revenues- United States' to come in at $119.11 million. The estimate indicates a change of +29.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Geographic Revenues- All other countries' should come in at $4.09 million. The estimate indicates a change of -0.1% from the prior-year quarter.
Shares of TransMedics have experienced a change of +33% in the past month compared to the +0.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TMDX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into TransMedics (TMDX) Q1: Wall Street Projections for Key Metrics
The upcoming report from TransMedics (TMDX - Free Report) is expected to reveal quarterly earnings of $0.29 per share, indicating a decline of 17.1% compared to the year-ago period. Analysts forecast revenues of $123.56 million, representing an increase of 27.6% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some TransMedics metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Net revenue by OCS product- OCS Lung net revenue' to reach $5.19 million. The estimate suggests a change of -8.4% year over year.
The consensus estimate for 'Net revenue by OCS product- OCS Liver net revenue' stands at $87.87 million. The estimate points to a change of +31.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net revenue by OCS product- OCS Heart net revenue' of $30.01 million. The estimate suggests a change of +28.6% year over year.
Analysts expect 'Geographic Revenues- United States' to come in at $119.11 million. The estimate indicates a change of +29.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Geographic Revenues- All other countries' should come in at $4.09 million. The estimate indicates a change of -0.1% from the prior-year quarter.
View all Key Company Metrics for TransMedics here>>>
Shares of TransMedics have experienced a change of +33% in the past month compared to the +0.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TMDX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>